Literature DB >> 27098365

Response to Stavropoulos.

Raymond R Townsend1, Israel Machin2, Jimmy Ren3, Angelina Trujillo4, Masato Kawaguchi5, Ujjwala Vijapurkar6, C V Damaraju6, Michael Pfeifer3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27098365      PMCID： PMC8031734          DOI： 10.1111/jch.12831

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  10 in total

1.  Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.

Authors:  William T Cefalu; Kaj Stenlöf; Lawrence A Leiter; John P H Wilding; Lawrence Blonde; David Polidori; John Xie; Daniel Sullivan; Keith Usiskin; William Canovatchel; Gary Meininger
Journal:  Diabetologia       Date:  2015-03-27       Impact factor: 10.122

2.  The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.

Authors:  James R Gavin; Melanie J Davies; Michael Davies; Ujjwala Vijapurkar; Maria Alba; Gary Meininger
Journal:  Curr Med Res Opin       Date:  2015-09-04       Impact factor: 2.580

3.  Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

Authors:  S Sha; D Polidori; T Heise; J Natarajan; K Farrell; S-S Wang; D Sica; P Rothenberg; L Plum-Mörschel
Journal:  Diabetes Obes Metab       Date:  2014-07-08       Impact factor: 6.577

Review 4.  Renal effects of canagliflozin in type 2 diabetes mellitus.

Authors:  Vlado Perkovic; Meg Jardine; Ujjwala Vijapurkar; Gary Meininger
Journal:  Curr Med Res Opin       Date:  2015-10-23       Impact factor: 2.580

5.  Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

Authors:  Bruce Neal; Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Peter Stein; Mehul Desai; Wayne Shaw; Joel Jiang; Frank Vercruysse; Gary Meininger; David Matthews
Journal:  Am Heart J       Date:  2013-06-24       Impact factor: 4.749

6.  Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.

Authors:  Keith Usiskin; Irina Kline; Albert Fung; Cristiana Mayer; Gary Meininger
Journal:  Postgrad Med       Date:  2014-05       Impact factor: 3.840

7.  Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.

Authors:  Matthew R Weir; Andrzej Januszewicz; Richard E Gilbert; Ujjwala Vijapurkar; Irina Kline; Albert Fung; Gary Meininger
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-10-20       Impact factor: 3.738

8.  Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.

Authors:  Raymond R Townsend; Israel Machin; Jimmy Ren; Angelina Trujillo; Masato Kawaguchi; Ujjwala Vijapurkar; Chandrasekharrao V Damaraju; Michael Pfeifer
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-12-10       Impact factor: 3.738

9.  Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Chrysoula Boutari; Vasilios G Athyros; Asterios I Karagiannis
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-04-21       Impact factor: 3.738

10.  Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.

Authors:  J-F Yale; G Bakris; B Cariou; D Yue; E David-Neto; L Xi; K Figueroa; E Wajs; K Usiskin; G Meininger
Journal:  Diabetes Obes Metab       Date:  2013-03-28       Impact factor: 6.577
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.